Trial: 202009136

A randomized, multicenter, double-blind phase 3 study of SAR439859 plus palbociclib versus letrozole plus palbociclib for the treatment of patients with ER (+), HER2 (-) breast cancer who have not received prior systemic anti-cancer treatment for advanced disease

Phase

III (Cancer Control)

Principal Investigator

Ma, Cynthia

Disease Site

Breast

Learn more about this study at: clinicaltrials.gov